02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
18:53 , Feb 22, 2019 |  BC Week In Review  |  Company News

NASA to test Pluristem's PLX cells for space mission-related indications

The NASA Ames Research Center will study the potential of placenta-based PLX cell therapies from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) to prevent and treat medical conditions resulting from space missions in astronauts under a...
02:06 , Feb 9, 2019 |  BioCentury  |  Politics, Policy & Law

Killing Part D rebates

HHS’s proposal to scrap the secret rebates drug manufacturers pay PBMs and health plans in Medicare Part D would help President Donald Trump fulfill promises to reduce drug prices. It would also reduce financial burdens...
21:04 , Jan 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro , patient sample, cell culture and rat studies identified an inhibitor of thrombin-mediated PAR1 activation that could help treat glioblastoma. In tumor samples from patients, PAR1 expression was higher than...
18:26 , Oct 19, 2018 |  BC Week In Review  |  Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
20:10 , Oct 18, 2018 |  BC Extra  |  Company News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
18:27 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Prevencio's HART PAD test detects PAD in diabetes patients

Prevencio Inc. (Kirkland, Wash.) said its HART PAD test diagnosed peripheral artery disease (PAD) in a cohort of 94 diabetic patients with 95% accuracy. Data were presented at the European Society of Cardiology meeting in...
17:38 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex in Phase III

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a single-blind Phase...
07:52 , Aug 21, 2018 |  BC Extra  |  Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III...
22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...